Healthcare: Agency health chief leaves for Celgene

Aoife Kilkenny, head of healthcare public affairs at Fleishman-Hillard, is quitting the agency to head up comms at multinational biopharmaceutical company Celgene.

Kilkenny is leaving next month after three years at F-H. Her new role will include overseeing the UK corporate communications for the firm's drugs portfolio. She will also concentrate on market access activities.

Celgene appeared in a documentary earlier this year examining the National Institute for Health and Clinical Excellence's drug approval process. Adam Wishart's documentary The Price of Life followed the process for a new cancer drug, Revlimid, which is made by Celgene.

F-H is currently recruiting for her replacement. Kilkenny joined F-H in 2006 as deputy head of healthcare public affairs from Media Strategy (PRWeek, 9 March 2006). She became head of the public affairs practice in March last year.

Kilkenny also previously worked as director of comms and public affairs at the Association of British Healthcare Industries and as a senior consultant at Hanover.

Earlier this month PRWeek revealed F-H was overhauling its medical education function following the departure of longstanding staffer Kate Hawker (PRWeek, 9 September).

F-H is merging its medical education practice The Remedy into its healthcare PR division, following the departure of two senior directors. The Remedy founder Hawker has left to set up a new medical comms shop with Charlotte Florence, a fellow director at the med ed practice.

Separately, F-H has been hired by International SOS, the medical assistance provider, which also specialises in international healthcare and security services.

The company has selected F-H to raise the profile of the organisation among its key stakeholders in the UK.

F-H London will build brand recognition of International SOS, positioning the organisation as a provider of expert services and consultancy in the travel risk management arena.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in